{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:11:45Z","timestamp":1780359105520,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020537","name":"Merck Sharp and Dohme Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015969","name":"Fay Fuller Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2017131"],"award-info":[{"award-number":["GNT2017131"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1193596"],"award-info":[{"award-number":["1193596"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1177991"],"award-info":[{"award-number":["1177991"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024879","name":"Janssen Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024879","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001136","name":"Australian and New Zealand College of Anaesthetists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100027043","name":"Milken Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013617","name":"American Society for Clinical Pathology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013617","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jad.2025.119502","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T02:33:53Z","timestamp":1748399633000},"page":"119502","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial \u2013 The KADS study"],"prefix":"10.1016","volume":"387","author":[{"given":"Mary Lou","family":"Chatterton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johana Kevin","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thao","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Faller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen K.","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Glozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard T.","family":"Baune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie T.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul B.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Glue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthi","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Hadzi-Pavlovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donel","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip B.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Berk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maree","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Somogyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrine","family":"Mihalopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.119502_bb0005","series-title":"All Employees, Average Weekly Total Cash Earnings, Average Age-Sex: By Detailed Occupation (ANZSCO 4 Digit)","author":"Australian Bureau of Statistics","year":"2014"},{"key":"10.1016\/j.jad.2025.119502_bb0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","article-title":"Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis","volume":"278","author":"Bahji","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.119502_bb0015","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/1472-6963-13-217","article-title":"Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P)","volume":"13","author":"Bouwmans","year":"2013","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.jad.2025.119502_bb0020","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jad.2022.09.083","article-title":"Cost-effectiveness of esketamine nasal spray compared to intravenous ketamine for patients with treatment-resistant depression in the US utilizing clinical trial efficacy and real-world effectiveness estimates","volume":"319","author":"Brendle","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.119502_bb0025","series-title":"CADTH Drug Reimbursment Review, Pharmacoeconomic Report, Esketamine Hydrochloride (Spravato) (Janssen Inc.), Indication: Major Depressive Disorder in Adults","author":"Canada's Drug and Health Technology Agency","year":"2021"},{"key":"10.1016\/j.jad.2025.119502_bb0030","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1586\/14737167.8.6.593","article-title":"Priority setting in health: origins, description and application of the Australian assessing cost-effectiveness initiative","volume":"8","author":"Carter","year":"2008","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.jad.2025.119502_bb0035","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12875-022-01839-z","article-title":"Economic evaluation of a Decision Support Tool to guide intensity of mental health care in general practice: the Link-me pragmatic randomised controlled trial","volume":"23","author":"Chatterton","year":"2022","journal-title":"BMC Prim Care"},{"key":"10.1016\/j.jad.2025.119502_bb0040","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s11121-017-0858-1","article-title":"Standards of evidence for conducting and reporting economic evaluations in prevention science","volume":"19","author":"Crowley","year":"2018","journal-title":"Prev. Sci."},{"key":"10.1016\/j.jad.2025.119502_bb0045","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial","volume":"76","author":"Daly","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2025.119502_bb0050","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1186\/s12888-021-03601-8","article-title":"Cost-utility analysis of esketamine and electroconvulsive therapy in adults with treatment-resistant depression","volume":"21","author":"Degerlund Maldi","year":"2021","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2025.119502_bb0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2217\/cer-2020-0276","article-title":"Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression","volume":"10","author":"Desai","year":"2021","journal-title":"J Comp Eff Res"},{"issue":"2","key":"10.1016\/j.jad.2025.119502_bb0060","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40258-023-00849-x","article-title":"Health service utilisation of people living with psychosis: validity of self-report compared with administrative data in a randomised controlled trial","volume":"22","author":"Dolar","year":"2023","journal-title":"Appl. Health Econ. Health Policy"},{"key":"10.1016\/j.jad.2025.119502_bb0065","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"10.1016\/j.jad.2025.119502_bb0070","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","article-title":"A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials","volume":"32","author":"Faria","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jad.2025.119502_bb0075","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/ijnp\/pyz039","article-title":"Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1)","volume":"22","author":"Fedgchin","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.119502_bb0080","first-page":"137","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2025.119502_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"20","author":"Husereau","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.jad.2025.119502_bb0090","series-title":"Esketamine for the Treatment of Treatment-resistant Depression: Effectiveness and Value","author":"Institute for Clinical and Economic Review","year":"2019"},{"key":"10.1016\/j.jad.2025.119502_bb0095","series-title":"Ketamine Therapy Among Patients With Treatment-Resistant Depression: A Double-blind, Randomised, Controlled Trial (the KADS Trial) - Clinical Trial Protocol & Statistical Analysis Plan","author":"Loo","year":"2021"},{"key":"10.1016\/j.jad.2025.119502_bb0100","first-page":"1","article-title":"Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial","author":"Loo","year":"2023","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.119502_bb0105","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1007\/s11136-016-1337-z","article-title":"Deriving population norms for the AQoL-6D and AQoL-8D multi-attribute utility instruments from web-based data","volume":"25","author":"Maxwell","year":"2016","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.jad.2025.119502_bb0110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2025.119502_bb0115","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jama.2023.1792","article-title":"Cost-effectiveness thresholds used by study authors, 1990-2021","volume":"329","author":"Neumann","year":"2023","journal-title":"Jama"},{"key":"10.1016\/j.jad.2025.119502_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102127","article-title":"Ketamine for the treatment of major depression: a systematic review and meta-analysis","volume":"62","author":"Nikolin","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jad.2025.119502_bb0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jagp.2019.10.008","article-title":"Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3","volume":"28","author":"Ochs-Ross","year":"2020","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2025.119502_bb0130","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.119502_bb0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40273-022-01220-z","article-title":"Cost-utility analysis of esketamine for patients with treatment-resistant depression in Italy","volume":"41","author":"Rognoni","year":"2023","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.jad.2025.119502_bb0140","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1176\/appi.ps.201900625","article-title":"Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States","volume":"71","author":"Ross","year":"2020","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.jad.2025.119502_bb0145","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725009449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725009449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:45:15Z","timestamp":1762249515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725009449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"alternative-id":["S0165032725009449"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.119502","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial \u2013 The KADS study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.119502","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119502"}}